摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2-氧代-2-吡啶-3-基-乙基)-氨基甲酸叔丁酯 | 473693-42-4

中文名称
(2-氧代-2-吡啶-3-基-乙基)-氨基甲酸叔丁酯
中文别名
——
英文名称
tert-butyl (2-oxo-2-(pyridin-3-yl)ethyl)carbamate
英文别名
tert-butyl N-(2-oxo-2-pyridin-3-ylethyl)carbamate
(2-氧代-2-吡啶-3-基-乙基)-氨基甲酸叔丁酯化学式
CAS
473693-42-4
化学式
C12H16N2O3
mdl
——
分子量
236.271
InChiKey
WSFAFVYGSMIUCY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    17
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    68.3
  • 氢给体数:
    1
  • 氢受体数:
    4

SDS

SDS:b9d5d3b41b6419a91f53deb45c839ba9
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS<br/>[FR] HYDANTOINAMIDES SUBSTITUÉS EN TANT QU'ANTAGONISTES D'ADAMTS7
    申请人:BAYER AG
    公开号:WO2021094434A1
    公开(公告)日:2021-05-20
    The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.
    该申请涉及公式(I)的替代咪唑酰脲作为ADAMTS7拮抗剂,以及它们的制备方法,它们单独或与其他药物联合用于治疗或预防疾病,特别是心血管疾病,包括动脉粥样硬化、冠状动脉疾病(CAD)、外周血管疾病(PAD)、动脉闭塞病或血管成形术后再狭窄。R1为氢、烷基、环烷基、杂环烷基、5-至6-成员杂芳基或苯基;R2为氢或烷基;A为5-成员杂芳基;Z为6-至10-成员芳基或5-至10-成员杂芳基;所有基团均可选择性地被取代。
  • [EN] NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS<br/>[FR] LIGANDS DU RECEPTEUR A L'ACETYLCHOLINE NICOTINIQUE
    申请人:ASTRAZENECA AB
    公开号:WO2005061510A1
    公开(公告)日:2005-07-07
    Acetylcholine receptor ligands of formula (I), wherein D, Ar1, E and Ar2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    乙酰胆碱受体配体的化学式(I),其中D、Ar1、E和Ar2如规范中所述,对映异构体,对映体,药用盐,制备方法,含有该化合物的药物组合物以及使用该化合物的方法。
  • Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
    申请人:Cheshire David
    公开号:US20050143379A1
    公开(公告)日:2005-06-30
    There are provided novel compounds of formula (I), wherein R 1 , R 2 , R 3 , T, U, X, Y, V and W are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain.
    提供了一种新化合物的公式(I),其中R1、R2、R3、T、U、X、Y、V和W如规范所定义,并且其药学上可接受的盐、对映体和外消旋体;以及它们的制备方法、含有它们的组合物和它们在治疗中的用途。这些化合物是一氧化氮合酶抑制剂,因此在治疗或预防炎症性疾病和疼痛方面特别有用。
  • Large conductance calcium-activated k channel opener
    申请人:——
    公开号:US20040127527A1
    公开(公告)日:2004-07-01
    A large conductance calcium-activated K channel opener comprising as an active ingredient a nitrogen-containing 5-membered heterocyclic compound represented by the following formula (I): 1 wherein X represents N—R 4 , O or S, R 1 and R 2 each independently represent hydrogen, halogen, carboxyl, amino, lower alkyl, lower alkoxycarbonyl, lower alkenyl, cyclo-lower alkyl, carbamoyl, aryl, heterocyclic or heterocyclic-substituted carbonyl group, R 3 represents aryl, heterocyclic or lower alkyl group, and R 4 represents hydrogen or lower alkyl group, or a pharmaceutically acceptable salt thereof.
    一种大导电性钙激活的K通道开放剂,包括以下式子(I)所表示的含氮5元杂环化合物作为活性成分:1其中,X代表N-R4,O或S,R1和R2各自独立地代表氢、卤素、羧基、氨基、低级烷基、低级烷氧羰基、低级烯基、环状低级烷基、氨基甲酰基、芳香族、杂环或杂环取代的羰基基团,R3代表芳香族、杂环或低级烷基基团,R4代表氢或低级烷基基团,或其药学上可接受的盐。
  • Nicotinic Acetylcholine Receptor Ligands
    申请人:Ernst Glen
    公开号:US20070249588A1
    公开(公告)日:2007-10-25
    Acetylcholine receptor ligands of formula (I), wherein D, Ar1, E and Ar2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    公式(I)的乙酰胆碱受体配体,其中D,Ar1,E和Ar2如规范所述,对映异构体,对映体,药学上可接受的盐,制备方法,包含制剂和使用方法的药物组合物。
查看更多